{"id":1360,"date":"2000-08-01T12:00:00","date_gmt":"2000-08-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse"},"modified":"2000-08-01T12:00:00","modified_gmt":"2000-08-01T10:00:00","slug":"neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/","title":{"rendered":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse"},"content":{"rendered":"<p>Die Reperfusions-Therapie beim akuten Myokardinfarkt ist nach wie vor ein umstrittenes Thema. Wir hatten uns bereits 1995 ausf\u00fchrlich damit besch\u00e4ftigt (AMB 1995, 29, 57 und 65). K\u00fcrzlich ver\u00f6ffentlichte die offizielle Zeitschrift der \u00c4rztekammer Berlin einen lesenswerten Diskussionsbeitrag von K.-P. Sch\u00fcren (1). Die Argumente f\u00fcr und gegen verschiedene Behandlungsverfahren und die neuen Entwicklungen werden hier mit [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Reperfusions-Therapie beim akuten Myokardinfarkt ist nach wie vor ein umstrittenes Thema. Wir hatten uns bereits 1995 ausf\u00fchrlich damit besch\u00e4ftigt (AMB 1995, 29, 57 und 65). K\u00fcrzlich ver\u00f6ffentlichte die offizielle Zeitschrift der \u00c4rztekammer Berlin einen lesenswerten Diskussionsbeitrag von K.-P. Sch\u00fcren (1). Die Argumente f\u00fcr und gegen verschiedene Behandlungsverfahren und die neuen Entwicklungen werden hier mit [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[1315,1344,1343,1345,1346,1347,5133,5134,1348,1349,78,1350,1351,2656,2896,2895,1352,1353,1354,74,1355,1356,527,528,87,88,1334,1357,1358,1359,1360,1361,324,1362,1363,1364,106,1338,1365,1366],"class_list":["post-1360","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abciximab","tag-admiral-studie","tag-alteplase","tag-assent-i-studie","tag-compass-studie","tag-escobar-studie","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-gusto-iib-studie","tag-gusto-iii-studie","tag-herzinfarkt","tag-hirudin","tag-intime-studie","tag-koronar-stent","tag-koronarangiografie","tag-koronarangiographie","tag-lanoteplase","tag-lysetherapie","tag-miti-studie","tag-myokardinfarkt","tag-npa","tag-nrmi-2-register","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-rapport-studie","tag-reteplase","tag-rpa","tag-saruplase","tag-shock-studie","tag-speed-studie","tag-stent","tag-stent-pami-studie","tag-streptokinase","tag-thrombolysetherapie","tag-thrombozytenaggregationshemmer","tag-timi-14-studie","tag-tnk-tpa","tag-tpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Die Reperfusions-Therapie beim akuten Myokardinfarkt ist nach wie vor ein umstrittenes Thema. Wir hatten uns bereits 1995 ausf\u00fchrlich damit besch\u00e4ftigt (AMB 1995, 29, 57 und 65). K\u00fcrzlich ver\u00f6ffentlichte die offizielle Zeitschrift der \u00c4rztekammer Berlin einen lesenswerten Diskussionsbeitrag von K.-P. Sch\u00fcren (1). Die Argumente f\u00fcr und gegen verschiedene Behandlungsverfahren und die neuen Entwicklungen werden hier mit [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2000-08-01T10:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2000\/08\/Abbildung-2000-57-3.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"14\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse\",\"datePublished\":\"2000-08-01T10:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/\"},\"wordCount\":2811,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2000\\\/08\\\/Abbildung-2000-57-3.gif\",\"keywords\":[\"Abciximab\",\"ADMIRAL-Studie\",\"Alteplase\",\"ASSENT-I-Studie\",\"COMPASS-Studie\",\"ESCOBAR-Studie\",\"GP-IIb\\\/IIIa-Rezeptor-Antagonisten\",\"GP-IIb\\\/IIIa-Rezeptor-Blocker\",\"GUSTO IIb-Studie\",\"GUSTO III-Studie\",\"Herzinfarkt\",\"Hirudin\",\"InTIME-Studie\",\"Koronar-Stent\",\"Koronarangiografie\",\"Koronarangiographie\",\"Lanoteplase\",\"Lysetherapie\",\"MITI-Studie\",\"Myokardinfarkt\",\"NPA\",\"NRMI-2-Register\",\"PCI\",\"Perkutane Koronarintervention\",\"Perkutane transluminale koronare Angioplastie\",\"PTCA\",\"RAPPORT-Studie\",\"Reteplase\",\"RPA\",\"Saruplase\",\"SHOCK-Studie\",\"SPEED-Studie\",\"Stent\",\"Stent-PAMI-Studie\",\"Streptokinase\",\"Thrombolysetherapie\",\"Thrombozytenaggregationshemmer\",\"TIMI 14-Studie\",\"TNK-tPA\",\"TPA\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/\",\"name\":\"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2000\\\/08\\\/Abbildung-2000-57-3.gif\",\"datePublished\":\"2000-08-01T10:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2000\\\/08\\\/Abbildung-2000-57-3.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2000\\\/08\\\/Abbildung-2000-57-3.gif\",\"width\":500,\"height\":310},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/","og_locale":"de_DE","og_type":"article","og_title":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse - Der Arzneimittelbrief","og_description":"Die Reperfusions-Therapie beim akuten Myokardinfarkt ist nach wie vor ein umstrittenes Thema. Wir hatten uns bereits 1995 ausf\u00fchrlich damit besch\u00e4ftigt (AMB 1995, 29, 57 und 65). K\u00fcrzlich ver\u00f6ffentlichte die offizielle Zeitschrift der \u00c4rztekammer Berlin einen lesenswerten Diskussionsbeitrag von K.-P. Sch\u00fcren (1). Die Argumente f\u00fcr und gegen verschiedene Behandlungsverfahren und die neuen Entwicklungen werden hier mit [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2000-08-01T10:00:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2000\/08\/Abbildung-2000-57-3.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"14\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse","datePublished":"2000-08-01T10:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/"},"wordCount":2811,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2000\/08\/Abbildung-2000-57-3.gif","keywords":["Abciximab","ADMIRAL-Studie","Alteplase","ASSENT-I-Studie","COMPASS-Studie","ESCOBAR-Studie","GP-IIb\/IIIa-Rezeptor-Antagonisten","GP-IIb\/IIIa-Rezeptor-Blocker","GUSTO IIb-Studie","GUSTO III-Studie","Herzinfarkt","Hirudin","InTIME-Studie","Koronar-Stent","Koronarangiografie","Koronarangiographie","Lanoteplase","Lysetherapie","MITI-Studie","Myokardinfarkt","NPA","NRMI-2-Register","PCI","Perkutane Koronarintervention","Perkutane transluminale koronare Angioplastie","PTCA","RAPPORT-Studie","Reteplase","RPA","Saruplase","SHOCK-Studie","SPEED-Studie","Stent","Stent-PAMI-Studie","Streptokinase","Thrombolysetherapie","Thrombozytenaggregationshemmer","TIMI 14-Studie","TNK-tPA","TPA"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/","name":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2000\/08\/Abbildung-2000-57-3.gif","datePublished":"2000-08-01T10:00:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2000\/08\/Abbildung-2000-57-3.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2000\/08\/Abbildung-2000-57-3.gif","width":500,"height":310},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1360"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1360\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}